In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia

por Martina Hüttl, Irena Markova, Denisa Miklankova, Iveta Zapletalova, Martin Poruba, Martin Haluzik, Ivana Vaněčkova, Hana Malinska
Publicado 2021

Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension

por Silvie Hojná, Hana Rauchová, Hana Malínská, Irena Marková, Martina Hüttl, František Papoušek, Michal Behuliak, Denisa Miklánková, Zdeňka Vaňourková, Jan Neckář, Michaela Kadlecová, Petr Kujal, Josef Zicha, Ivana Vaněčková
Publicado 2021